Expert Ratings For OptimizeRx
Portfolio Pulse from Benzinga Insights
OptimizeRx (NASDAQ: OPRX) has received diverse analyst ratings over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 12.31% to $14.6. Analysts from firms like Stifel, JMP Securities, and RBC Capital have maintained positive ratings, reflecting optimism about the company's future performance.
May 15, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OptimizeRx has received a mix of bullish and somewhat bullish ratings from analysts over the past three months. The average 12-month price target has increased by 12.31% to $14.6, indicating positive sentiment. Analysts from Stifel, JMP Securities, and RBC Capital have maintained their positive ratings.
The increase in the average price target and the maintenance of positive ratings by multiple analysts suggest a positive short-term outlook for OptimizeRx. The company's strong revenue growth and efficient financial management further support this sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100